Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups

NCT00711295 is registered in ClinicalTrials.gov with Alachua Government Services, Inc. as lead sponsor.

NCT NCT00711295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00711295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups
Lead sponsor
Alachua Government Services, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2008
Completion date
October 31, 2010
Enrollment
3,583 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

influenza